A Study of ALPN-303 in Adult Healthy Volunteers

NCT05034484 | Completed Phase 1

• 1 other identifier: AIS-D01
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 2

Brief Summary

This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug effects the immune system) of a single dose of an investigational drug called ALPN-303. Multiple dose levels will be tested.

Conditions

Healthy Volunteers

Keywords

Healthy Volunteer; BAFF; APRIL

Outcome Measures

Primary Outcomes (1)

• Treatment-emergent Adverse Events (TEAE)

  Type, incidence, and severity of TEAE as assessed by CTCAE

  Day 1 through Day 30

Study Arms (4)

ALPN-303 Regimen A

EXPERIMENTAL

Drug: ALPN-303

Placebo Regimen A

PLACEBO COMPARATOR

Drug: Placebo

ALPN-303 Regimen B

EXPERIMENTAL

Drug: ALPN-303

Placebo Regimen B

PLACEBO COMPARATOR

Drug: Placebo

Interventions

ALPN-303 DRUG

Multiple dose levels will be evaluated.

ALPN-303 Regimen A; ALPN-303 Regimen B

Placebo DRUG

Placebo will be administered

Placebo Regimen A; Placebo Regimen B

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able and willing to provide written informed consent
• Body mass index 18 to 32 kg/m2
• Agree to avoid strenuous physical activity for 2 days prior to each study visit
• Agree to use highly effective contraception during the study (all participants) and for 90 days after study drug dosing (males) or for 60 days after study drug dosing (females)
• Male participants must refrain from donating sperm during the study and for 90 days after study drug dosing
• Female participants must not be pregnant or breastfeeding and must refrain from donating ova during the study and for 60 days after study drug dosing
• Must have completed vaccination against SARS-CoV-2 at least 4 weeks prior to study drug dosing

You may not qualify if:

• Any current disease, condition, or treatment that could interfere with the study, interfere with interpretation of the data, or pose an unacceptable risk to the participant
• History or symptoms of significant psychiatric disease; mild, resolved depression or anxiety is acceptable
• History of immunological disorders, auto-immune disorders, acquired or congenital immune deficiency; see protocol for clarifications/exceptions
• History of significant hepatic or renal disease or impairment
• Evidence of an active or suspected cancer or a history of malignancy within the previous 3 years; see protocol for exceptions
• History of major organ transplantation with an existing functional graft
• Use or receipt of prescription medications, over-the-counter medications, herbal remedies, or investigation products (study drugs) within protocol-defined timeframes prior to study entry; hormone replacement therapy initiated at least 2 months prior to Screening is acceptable
• Significant loss of blood or blood product (including donation) over 500 mL or transfusion of any blood product during Screening or within 3 months of Screening
• Unwilling to refrain from alcohol use ≥ 48 hours prior to Study Day -1.
• Known hypersensitivity, allergy, or intolerance to ALPN-303, Fc-based biologic therapy, or any of the excipients contained in the ALPN-303 formulation
• Immunization with any live vaccine within 6 weeks prior to study drug administration, or expected to require any live vaccines during the study or within 6 weeks after receiving study drug
• Acceptable laboratory assessments at Screening and Day -1
• Positive screen for drugs of abuse or alcohol at Screening or Day -1
• Positive tests for infectious disease (HIV, hepatitis B, hepatitis C, SARS-CoV-2)
• Acute infection during or within 4 weeks prior to Screening

Sponsors & Collaborators

• Alpine Immune Sciences, Inc.: lead

Study Sites (2)

Investigative Site

Brisbane, Queensland, 4006, Australia

Location

Investigative Site

Melbourne, Victoria, 3004, Australia

Location

Study Officials

• Stanford Peng, MD PhD

  Alpine Immune Sciences, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 26, 2021
• First Posted: September 5, 2021
• Study Start: November 15, 2021
• Primary Completion: February 27, 2023
• Study Completion: February 27, 2023
• Last Updated: May 9, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

AU (2)